Search hospitals
>
California
>
San Diego
Kaiser Permanente-San Diego Zion
Claim this profile
San Diego, California 92120
Global Leader in Lung Cancer
Global Leader in Breast Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Breast cancer
Conducts research for Cancer
126 reported clinical trials
10 medical researchers
Summary
Kaiser Permanente-San Diego Zion is a medical facility located in San Diego, California. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Cancer and other specialties. Kaiser Permanente-San Diego Zion is involved with conducting 126 clinical trials across 310 conditions. There are 10 research doctors associated with this hospital, such as Robert M. Cooper, Helen H. Moon, Gary L. Buchschacher, and Richard Green, MD.
Area of expertise
Lung Cancer
Kaiser Permanente-San Diego Zion has run 33 trials for Lung Cancer. Some of their research focus areas include:
Breast Cancer
Kaiser Permanente-San Diego Zion has run 20 trials for Breast Cancer. Some of their research focus areas include:
Top PIs
Robert M. Cooper
Kaiser Permanente Downey Medical Center
8 years of reported clinical research
Helen H. Moon
Kaiser Permanente-Riverside
9 years of reported clinical research
Gary L. Buchschacher
Kaiser Permanente-Anaheim
8 years of reported clinical research
Richard Green, MD
Kaiser Permanente Los Angeles Medical Center
10 years of reported clinical research
Clinical Trials running at Kaiser Permanente-San Diego Zion
Lung Cancer
Ovarian Cancer
Breast Cancer
Bladder Cancer
Non-Small Cell Lung Cancer
Breast cancer
Esophageal cancer
Prostate Cancer
Glioblastoma
Cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting
2 awards
Phase 3
27 criteria
Thoracotomy vs Thoracoscopy
for Metastatic Osteosarcoma
This phase III trial compares the effect of open thoracic surgery (thoracotomy) to thoracoscopic surgery (video-assisted thoracoscopic surgery or VATS) in treating patients with osteosarcoma that has spread to the lung (pulmonary metastases). Open thoracic surgery is a type of surgery done through a single larger incision (like a large cut) that goes between the ribs, opens up the chest, and removes the cancer. Thoracoscopy is a type of chest surgery where the doctor makes several small incisions and uses a small camera to help with removing the cancer. This trial is being done evaluate the two different surgery methods for patients with osteosarcoma that has spread to the lung to find out which is better.
Recruiting
2 awards
Phase 3
7 criteria
Cemiplimab
for Non-Small Cell Lung Cancer
This phase II/III Expanded Lung-MAP treatment trial compares the effect of adding cemiplimab to docetaxel and ramucirumab versus docetaxel and ramucirumab alone in treating patients with non-small cell lung cancer that is stage IV or that has come back after a period of improvement (recurrent). Cemiplimab is a monoclonal antibody that stimulates the immune system by blocking the PD-1 pathway. Tumors use the PD-1 pathway to escape attacks from the immune system. By blocking the PD-1 pathway, cemiplimab may help the immune system recognize and attack tumor cells. Docetaxel is in a class of medications called taxanes. It stops tumor cells from growing and dividing and may kill them. Ramucirumab is a monoclonal antibody that may prevent the growth of new blood vessels that tumors need to grow. Adding cemiplimab to usual treatment, docetaxel and ramucirumab, may kill more tumor cells compared to docetaxel and ramucirumab alone in treating patients with stage IV or recurrent non-small cell lung cancer.
Recruiting
1 award
Phase 2 & 3
19 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Kaiser Permanente-San Diego Zion?
Kaiser Permanente-San Diego Zion is a medical facility located in San Diego, California. This center is recognized for care of Lung Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Breast cancer, Cancer and other specialties. Kaiser Permanente-San Diego Zion is involved with conducting 126 clinical trials across 310 conditions. There are 10 research doctors associated with this hospital, such as Robert M. Cooper, Helen H. Moon, Gary L. Buchschacher, and Richard Green, MD.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.